EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Non‐Invasive Assessment of Perineural Invasion Density: A Novel Marker for Prognosis and Treatment Stratification in Prostate Cancer

Bohao Liu iD, Long Zhang, Weian Zhu iD, Meng Yang, Xiang Liu, Xiaoyang Li, Peng Qin, Zhengxu Lin, Qian Cai iD, Jiayu Zheng iD, Xiao Zhao iD, Chen Zou und 9 weitere

Advanced Science · 31.10.2026

DOI: 10.1002/advs.78460 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 31.10.2026. Verfasst von Bohao Liu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Third Affiliated Hospital of Sun Yat-Sen University, Clinical Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We established and validated perineural invasion density (PNID) as a superior prognostic marker and developed an MRI–based AI model for its preoperative prediction. In this multicenter study of 1091 PCa patients undergoing radical prostatectomy, we evaluated PNID's association with biochemical recurrence (BCR) and radiographic progression–free survival (rPFS). We also analyzed concurrent β–blocker or antimuscarinic use with adjuvant ADT. A deep learning model was developed in a primary cohort (n = 523) and validated in two external cohorts (n = 317, 251). High–PNID was an independent prognostic factor for BCR (HR 4.06, 95% CI: 2.75–5.97, P < 0.001) and rPFS (HR 4.61, 95% CI: 2.97–7.16, P < 0.001). Notably, concurrent β–blocker use was significantly associated with favorable BCR outcomes exclusively in the High–PNID subgroup (HR 0.32, 95% CI: 0.12–0.84, P = 0.021), with no benefit in the Non–High PNID population or with antimuscarinics. The AI model showed excellent performance predicting High–PNID, with AUCs of 0.917 (training), 0.842 (internal validation), 0.889 and 0.915 (external validations). Model–identified High–PNID patients had significantly worse outcomes. PNID surpasses traditional PNI in prognostic accuracy and identifies a high–risk phenotype. High–PNID may define a subgroup benefiting from adjuvant β–blocker therapy, providing an exploratory clinical rationale for targeting the nerve–tumor microenvironment in stratified subpopulations. Hence, this model may be a reliable, non–invasive tool for preoperative identification of this high–risk subgroup, aiding clinicians in personalized risk stratification and treatment planning.

Schlagwörter

Stichwörter der Autor:innen

artificial intelligenceperineural invasionprognosisprostate cancer

Autor:innen und Institutionen

  • Department of Urology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Department of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Urology, Yan'an Hospital Affiliated to Kunming Medical University, Kunming Medical University, Kunming, China.
  • Department of Radiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Urology, Peking University People's Hospital, Peking University, Beijing, China.
  • Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.

ORCID-Profile: Bohao Liu, Weian Zhu, Qian Cai, Jiayu Zheng, Xiao Zhao, Xuan Wen, Longhao Xu, Wenlong Zhong, Yun Luo

Förderung

  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Third Affiliated Hospital of Sun Yat-Sen University, Clinical Research Program
  • Fundamental Research Funds for the Central Universities
  • Sun Yat-Sen Memorial Hospital Clinical Research 5010 Program
  • Science and Technology Projects in Guangzhou
  • Natural Science Foundation of Guangdong Province, China
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Liu, B., Zhang, L., Zhu, W., Yang, M., Liu, X., Li, X., Qin, P., Lin, Z., Cai, Q., Zheng, J., Zhao, X., Zou, C., Wen, X., Xu, L., Wu, D., Zhang, L., Zhang, C., Li, K., Wang, C., …, & Luo, Y. (2026). Non‐Invasive Assessment of Perineural Invasion Density: A Novel Marker for Prognosis and Treatment Stratification in Prostate Cancer. Advanced Science. https://doi.org/10.1002/advs.78460

Vancouver

Liu B, Zhang L, Zhu W, Yang M, Liu X, Li X, et al. Non‐Invasive Assessment of Perineural Invasion Density: A Novel Marker for Prognosis and Treatment Stratification in Prostate Cancer. Advanced Science. 2026. doi:10.1002/advs.78460

BibTeX
@article{Liu2026,
  author = {Liu, Bohao and Zhang, Long and Zhu, Weian and Yang, Meng and Liu, Xiang and Li, Xiaoyang and Qin, Peng and Lin, Zhengxu and Cai, Qian and Zheng, Jiayu and Zhao, Xiao and Zou, Chen and Wen, Xuan and Xu, Longhao and Wu, Daqin and Zhang, Lin and Zhang, Cuilian and Li, Kaiwen and Wang, Chunhui and Zhong, Wenlong and Luo, Yun},
  title = {Non‐Invasive Assessment of Perineural Invasion Density: A Novel Marker for Prognosis and Treatment Stratification in Prostate Cancer},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.78460}
}
Kostenlos starten →